TÜBINGEN, Germany/ BOSTON, USA/ BASEL, Switzerland, March 30, 2021 / B3C newswire / -- CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Advanced Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed bio-therapeutics, today announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.
Celonic Group, a global contract development and manufacturing organization (CDMO) specialized in development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, has entered a long-term lease agreement for a new production site and office space spanning 91,500 square feet (8,500 sqm) in the WST-222 building at the Novartis-operated Life Science Park Rheintal. In this recently-announced life science park in Stein AG (Switzerland), Celonic will establish development and GMP production capacities for Cell & Gene Therapies (Cell & Gene), next-generation vaccines, and innovative biopharmaceuticals, to support clients from early clinical trials through commercialization.
Celonic Group, a contract development and manufacturing organization (CDMO), announced on Feb. 25, 2021 that it has entered into a long-term lease agreement for a new production site and office space at the Novartis-operated Life Science Park Rheintal in Stein, Switzerland.
Intravacc has partnered with contract development and manufacturing organisation (CDMO) Celonic Group for the design, development and production of a Covid-19 vaccine.